Translation and Validation of the Canadian-French Version of the Banff Patellofemoral Instability Instrument (BPII...

Patient-reported outcome measures are essential tools for assessing function and quality of life. The Banff Patellofemoral Instability Instrument Version 2.0 (BPII 2.0) is specifically designed to evaluate adolescents and adults experiencing patellofemoral instability (PFI).

Because no French version was available, this study aimed to translate and validate a Canadian-French (CF) version of the BPII 2.0.

Cohort study (Diagnosis); Level of evidence, 3.

The BPII 2.0 was translated using a forward-backward translation method (BPII 2.0-CF), following guidelines from the American Association of Orthopaedic Surgeons and the Institute for Work & Health. Participants aged ≥14, fluent in French, and with a confirmed diagnosis of PFI were included. Patients completed the questionnaire at their initial consultation, 7 days later, and 6 months after treatment. Construct validity was assessed through Spearman correlation with the Kujala score. Internal consistency was evaluated using the Cronbach alpha coefficient, and test-retest reliability using the intraclass correlation coefficient (ICC). Responsiveness to change was analyzed using the Wilcoxon signed-rank test and the corresponding effect size r.

A total of 45 participants were included (female, n = 33; 73%), with a median age of 21 years (range, 14-54). The median symptom duration before consultation was 48 months (range, 0.5-480.0). Mean ± SD BPII 2.0-CF scores were 38.46 ± 14.48 (N = 45), 39.52 ± 15.99 (n = 34), and 60.99 ± 20.24 (n = 29) at baseline, day 7, and 6 months after surgery, respectively. No floor or ceiling effects were observed. The construct validity of the translated BPII 2.0 and the French Kujala score at baseline was fair and statistically significant (r = 0.56; 95% CI, 0.28-0.77; P < .001). Internal consistency was acceptable with Cronbach alpha coefficient of .87. Retest reliability was good with an ICC of 0.75 (95% CI, 0.56-0.87; P < .001), and the response to change showed strong reactivity with an effect size of 0.79 (95% CI, 0.60-0.90; P < .001).

The CF version of the BPII 2.0 is a valid, reliable, and appropriate tool for assessing patients with PFI. The rigorous translation and validation process supports its use in Francophone clinical settings.